GoodRx (GDRX)
(Delayed Data from NSDQ)
$7.19 USD
+0.11 (1.55%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $7.24 +0.05 (0.70%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth F Momentum D VGM
Price, Consensus and EPS Surprise
GDRX 7.19 +0.11(1.55%)
Will GDRX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for GDRX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for GDRX
Is GoodRx (GDRX) Outperforming Other Medical Stocks This Year?
ELV vs. GDRX: Which Stock Is the Better Value Option?
GDRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
ELV or GDRX: Which Is the Better Value Stock Right Now?
Wall Street Analysts Predict a 29.1% Upside in GoodRx Holdings, Inc. (GDRX): Here's What You Should Know
Encompass Health (EHC), Piedmont to Build Loganville Facility
Other News for GDRX
Investors in GoodRx Holdings, Inc. Should Contact Levi & Korsinsky LLP Before June 21, 2024 to Discuss Your Rights – GDRX
GoodRx Announces Date for 2024 Investor Day
NCPDP Foundation Funds New Project to Streamline REMS Process for the Industry
NCPDP's National Facilitator Model Pilot Project Enters Second Phase
Analysts Are Bullish on These Healthcare Stocks: GoodRx Holdings (GDRX), Arcutis Biotherapeutics (ARQT)